Journey Medical CORP 8-K filings

Journey Medical Corporation announced second quarter 2026 financial results, showcasing a 23% year-over-year revenue increase to $18.5 million and a substantial reduction in net loss.

Journey Medical Corporation announced first quarter 2026 financial results, reporting a 21% year-over-year increase in total revenues to $16.0 million, driven by strong performance in Emrosi.

Journey Medical Corporation has secured contracts with three major group purchasing organizations, expanding Emrosi access to 85% of U.S. commercial lives.

Journey Medical Corporation announced full-year 2025 financial results, reporting a 10% revenue increase driven by the successful launch of Emrosi, alongside improved gross margins and reduced net loss.

Journey Medical Corporation announced robust third-quarter 2025 financial results, driven by a 21% year-over-year revenue increase and significant growth in its key dermatology product, Emrosi.

Journey Medical Corporation amended its credit agreement, extending the term loan maturity to June 2028 and revising principal repayment terms based on revenue thresholds.

Journey Medical Corporation has entered into a new At Market Issuance Sales Agreement to potentially sell up to 3,750,000 shares of common stock, replacing a prior agreement.

Journey Medical Corporation reported a slight revenue increase to $15.0 million in Q2 2025, driven by Emrosi sales, but net loss widened to $3.8 million.

Journey Medical Corporation announced a significant expansion in pharmacy benefit coverage for its recently launched rosacea treatment, Emrosi, now covering 65% of commercial lives in the U.S.

Journey Medical Corporation announced the filing of its Fourth Amended and Restated Certificate of Incorporation, effective June 24, 2025, which includes provisions for officer exculpation and other corporate governance updates, following approval at its 2025 Annual Meeting of Stockholders.

Journey Medical Corporation (Nasdaq: DERM) announced its inclusion in the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective June 27, 2025, a move anticipated to boost investor visibility and institutional interest.

Journey Medical Corporation announced its Q1 2025 financial results, highlighting a strong start to the commercial launch of Emrosi and consistent revenue compared to the previous year.

Journey Medical Corporation promotes Ramsey Alloush, General Counsel, to the position of Chief Operating Officer, effective April 1, 2025.

Journey Medical Corporation announces its full-year 2024 financial results, highlighting FDA approval and initial distribution of Emrosi, along with total revenues of $56.1 million.

Journey Medical Corporation announces the launch and first prescriptions filled for Emrosi, a treatment for inflammatory lesions of rosacea in adults.

Journey Medical Corporation reaffirms its financial guidance for 2024 and announces the commercial launch plan for its newly approved dermatological product, Emrosi.

Journey Medical Corporation reported a 4% decrease in revenue for Q3 2024 compared to the same period last year, but also announced the FDA approval of their new drug, Emrosi.

Journey Medical Corporation announced FDA approval for Emrosi, a rosacea treatment, and released preliminary financial results for the third quarter of 2024.

Journey Medical Corporation announced a 14% sequential increase in revenue for the second quarter of 2024, along with positive adjusted EBITDA and progress on its DFD-29 drug application.

Journey Medical Corporation has amended its credit agreement to increase its loan facility by $5 million, contingent on FDA approval for its DFD-29 product, and has appointed Michael C. Pearce to its Board of Directors.

Journey Medical Corporation's stockholders approved an amendment to the 2015 Stock Incentive Plan, increasing authorized shares and extending the plan's term, and elected five directors at their 2024 annual meeting.

Journey Medical Corporation announced a 7% year-over-year revenue increase for the first quarter of 2024, driven by strong performance of key products and the acceptance of their New Drug Application for DFD-29 by the FDA.

Journey Medical Corporation has appointed Joseph Benesch as its permanent Chief Financial Officer, effective April 26, 2024, after he served as interim CFO since January 2023.

Journey Medical Corporation reported a 7% increase in total revenue for 2023, reaching $79.2 million, alongside significant cost savings and progress in their drug development pipeline.